Pharmacopsychiatry 2019; 52(02): 52-62
DOI: 10.1055/a-0574-0088
Review
© Georg Thieme Verlag KG Stuttgart · New York

Efficacy, Tolerability, and Safety of Blonanserin in Schizophrenia: An Updated and Extended Systematic Review and Meta-Analysis of Randomized Controlled Trials

Taro Kishi
1   Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan
,
Yuki Matsui
1   Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan
,
Yuki Matsuda
2   Department of Psychiatry, Jikei University School of Medicine, Minato-ku, Tokyo, Japan
,
Asuka Katsuki
3   Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan
,
Hikaru Hori
3   Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan
,
Hiroko Yanagimoto
4   Department of Neuropsychiatry, Kurume University, Kurume, Fukuoka, Japan
5   Cognitive and Molecular Research Institute of Brain Diseases, Kurume University, Kurume, Fukuoka, Japan
,
Kenji Sanada
6   Department of Psychiatry, Showa University School of Medicine, Tokyo, Japan
,
Kiichiro Morita
5   Cognitive and Molecular Research Institute of Brain Diseases, Kurume University, Kurume, Fukuoka, Japan
,
Reiji Yoshimura
3   Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan
,
Yoshihisa Shoji
4   Department of Neuropsychiatry, Kurume University, Kurume, Fukuoka, Japan
5   Cognitive and Molecular Research Institute of Brain Diseases, Kurume University, Kurume, Fukuoka, Japan
,
Katsuhiko Hagi
7   Sumitomo Dainippon Pharma Co., Ltd., Medical Affairs, Tokyo, Japan
,
Nakao Iwata
1   Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan
› Author Affiliations
Further Information

Publication History

received 20 November 2017
revised 16 January 2018

accepted 01 February 2018

Publication Date:
07 March 2018 (online)

Preview

Abstract

Introduction We conducted an updated systematic review and meta-analysis of randomized controlled trials (RCTs) comparing blonanserin with other antipsychotics (amisulpride, aripiprazole, haloperidol, paliperidone, and risperidone).

Methods Weighted mean difference (WMD), risk ratio, and number needed to harm (NNH) with 95% confidence intervals (95% CIs) were calculated using random-effects model.

Results Ten RCTs (n=1521) were included in this study. Blonanserin was superior to aripiprazole in improvement of Positive and Negative Syndrome Scale total scores (WMD=−10.62, 95% CI=−17.67 to −3.560, p=0.003). Blonanserin was associated with a higher incidence of all-cause discontinuation (RR=1.373, 95% CI=1.088–1.734, p=0.008, NNH=11), akathisia, extrapyramidal disorder, and agitation/excitement and a lower risk of hyperprolactinemia compared with risperidone + paliperidone.

Discussion The current meta-analytic study did not update the comparison of blonanserin vs. haloperidol because there were no new RCTs. Our results suggest that the efficacy of blonanserin for schizophrenia is comparable with that of other antipsychotics, and blonanserin seems to be well tolerated.

Supporting Information